84.2% of the patients had reduction of their median seizure frequency at the 12-month period. However, there were no significant difference on the seizure control rate based on clinical characteristics. There were no statistically significant differences between male and female patients on their improvement rate across the four times on average. Lacosamide is an effective well tolerate drug for patients with focal epilepsy.Lacosamide is an effective well tolerate drug for patients with focal epilepsy.Intracellular protein degradation is mediated selectively by the Ubiquitin Proteasome System (UPS) and autophagic-lysosomal system in mammalian cells. Many cellular and physiological processes, such as cell division, cell differentiation, and cellular demise. are fine-tuned via the UPS-mediated protein degradation. Notably, impairment of UPS contributes to human disorders including cancer and neurodegeneration. The proteasome-dependent N-degron pathways mediate the degradation of proteins through their destabilizing amino-terminal residues. Recent advances unveiled that targeting N-degron proteolytic pathways can aid in sensitizing some cancer cells to chemotherapeutic agents. Furthermore, interestingly, exploiting the N-degron feature, the simplest degradation signal in mammals, and fusing it to a ligand specific for Estrogen-Related Receptor alpha (ERRa) has demonstrated its utility in ERRa knockdown, via Nterminal dependent degradation, and also its efficiency in the inhibition of growth of breast cancer cells. These recent advances uncover the therapeutic implications of targeting and exploiting N-degron proteolytic pathways to curb growth and migration of cancer cells. To design controlled release topical delivery of mupirocin for treatment of skin infection. Mupirocin is an antibacterial drug. Mupirocin works to kill the bacteria which include strains of Staphylococcus aureus and Streptococcus pyogenes. It is also used for treatment of inflammation of a hair follicle. Halflife of mupirocin is only 20-40 min. It has very slight solubility in water. Patent literature had shown work on ointment, antibiotic composition, nasal and topical composition. Emulgel is a duel control release system for topical delivery of hydrophobic drugs. was to formulate emulgel with controlled delivery of mupirocin using Sepineo P 600. Soya oil, tween 80 and polyethylene glycol 400 (Oil Surfactant Cosurfactant) was used for emulsion formulation. Emulgel was optimized by 32 factorial design. Sepineo P 600 and hydroxy propyl methyl cellulose K4M was used as independent variable. Drug excipient compatibility analysis was carried out by FTIR, UV and DSC spectra. Emulgel was evaluated for its physical characterization, in-vitro release, ex-vivo release, antimicrobial and antiinflammatory study. DSC, UV and FTIR analysis confirmed drug excipient compatibility. FE SEM showed size range in between 228-255 nm. Zeta potential was found to be -25.1mV, which showed good stability of the emulsion. Design expert software showed F2 as optimized batch. Release studies indicated controlled release of drug form Sepineo P600 gel due to its higher gelling capacity. Batch F2 showed comparable results with marketed formulation against Staphylococcus aureus. click here For batch F2, 40 μg/ml was the minimal inhibitory concentration. Antimicrobial and anti-inflammatory study proved successful development of stable controlled release mupirocin emulgel.Antimicrobial and anti-inflammatory study proved successful development of stable controlled release mupirocin emulgel. On 11st-March 2020, WHO announced novel coronavirus infectious (COVID-19) as a pandemic. A new coronavirus pneumonia (NCP) that emerge on 31 December 2019 from China and quickly became a Public Health Emergency of International Concern (PHEIC). In the absence of evidence based proven prophylactic or therapeutic options, chloroquine/hydroxychloroquine (CQ/HCQ) patened as first line choice in COVID-19 treatment, which raised concerns about drug poisoning especially ocular toxicity. This study aim to investigate the possibility of ocular toxicity and the need for ophthalmic counseling to prescribe this therapeutic protocol. All the articles that were most relevant to the COVID-19 therapeutic or prophylactic options and CQ derivative ocular toxicity, were founded by a literature search and were thoroughly reviewed. Anecdotal recent reports introduce CQ/HCQ as an effective therapeutic or prophylactic choice for COVID-19. Because of the short time prescribe and the insignificant cumulative dose of the drug on the one hand and higher risk of cross infection during ophthalmic examination on the other hand, ophthalmologic consult is not recommended except in high-risk patients for retinal toxicity. This study recommended ophthalmic evaluation before CQ/HCQ prescription for treatment or prophylaxis of COVID-19 only in preexisting maculopathy.This study recommended ophthalmic evaluation before CQ/HCQ prescription for treatment or prophylaxis of COVID-19 only in preexisting maculopathy. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been associated with increased risk of diabetic ketoacidosis (DKA) in both people with type 1 and type 2 diabetes mellitus. Too few studies using data from high-quality registries exist, that attempt to determine the real-world impact of the increasing use of this drug. The aim of this study was to investigate the incidence and risk of DKA in connection with SGLT2i treatment in Denmark between 2013-2017. A nationwide retrospective cohort of people with type 2 diabetes mellitus using SGLT2i or glucagon-like peptide-1 receptor agonists (GLP1-RA) was established and analysed using both Cox-proportional hazard regression and Kaplan-Meier survival analysis. The 37,058 individuals included in the cohort, were made up of SGLT2i (10,923), GLP1-RA (18,849), SGLT2i+insulin (2,069), and GLP1-RA+insulin (10,178) users. The incidence rate (IR) of DKA was 0.84 (95% CI 0.49- 1.44) and 0.53 (95% CI 0.36-0.77) for the SGLT2i and GLP1-RA groups, respectively. There was no statistically significant increase in the risk for DKA with SGLT2i use (HR 1.02, 95% CI, 0.44-2.36). However, for the SGLT2i+insulin and GLP1-RA+insulin groups, IRs were 3.47 (95% CI 1.92-6.27) and 0.97 (95% CI 0.68-1.37) respectively, and the risk was statistically significantly higher (HR 5.42, 95% CI 2.16-13.56). We observed no significant increase in risk of DKA for SGLT2i users compared to GLP1-RA. However, a significantly higher IR of DKA was observed with concomitant insulin use, and the risk of DKA was considerably higher for the SGLT2 group using insulin.We observed no significant increase in risk of DKA for SGLT2i users compared to GLP1-RA. However, a significantly higher IR of DKA was observed with concomitant insulin use, and the risk of DKA was considerably higher for the SGLT2 group using insulin.